

Supplementary Data

Table. Study drug dosing in the MPD cohort (n = 52) and the overall study population (N = 84)

	Carfilzomib		Lenalidomide		Dexamethasone	
	MPD	Overall	MPD	Overall	MPD	Overall
Cycles started, median (range)	9.5 (1–45)	8.5 (1–55)	8.5 (1–44)	7.0 (1–50)	9.0 (1–44)	7.0 (1–50)
Number of doses, median (range)	51.5 (2–246)	46.0 (2–254)	152.0 (2–885)	134.5 (2–1049)	28.0 (1–156)	20.0 (1–156)
Dose reduction due to AE, n (%)	4 (7.7)	4 (4.8)	--	--	--	--
Dose reduction for any reason, n (%)	--	--	18 (34.6)	25 (29.8)	22 (42.3)	28 (33.3)
Dose interruption, n (%)	2 (3.8)	2 (2.4)	--	--	--	--
Dose delay, n (%)	36 (69.2)	55 (65.5)	--	--	--	--
Dose missed, n (%)	34 (65.4)	54(64.3)	39 (75.0)	59 (70.2)	33 (63.5)	59 (70.2)
Average dose per administration, median (range)*	26.7 (17–27)	24.8 (15–27)	25.0 (11–25)	24.0 (10–25)	40 (4–40)	40 (4–40)
Cumulative dose across cycles, median (range)*	1322.5 (40– 6628)	944.5 (30–6628)	3120 (50–22125)	2825 (50–22125)	840 (4–6240)	730 (4–6240)

*mg/m² for carfilzomib and mg for dexamethasone and lenalidomide.